Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date

This article was originally published in PharmAsia News

Executive Summary

Arena Pharmaceuticals has won an early race against Vivus and Orexigen Therapeutics in finding a commercialization partner for its obesity drug candidate lorcaserin. The three companies are vying to bring the first new obesity drug to the market in over a decade, with U.S. FDA action dates for the three candidates scheduled between October and January
Advertisement

Related Content

Takeda Bulks Up In Obesity With Orexigen Deal
Takeda Bulks Up In Obesity With Orexigen Deal
Arena Optimistic About Lorcaserin But Analysts More Reserved
Arena Optimistic About Lorcaserin But Analysts More Reserved
Eisai's Newly Acquired Lorcaserin Faced With Regulatory Hurdle After Qnexa Advisory Committee Vote
Eisai's Newly Acquired Lorcaserin Faced With Regulatory Hurdle After Qnexa Advisory Committee Vote
Arena Gets Financing Boost, Lorcaserin Advisory Committee Date
Arena Gets Financing Boost, Lorcaserin Advisory Committee Date
Advertisement
UsernamePublicRestriction

Register

SC075384

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel